retatrutide safety profile Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Product Information & Safety

, -l- ,

The table flags an eGFR below 60 mL/min/1.73m2 as a risk factor, describing it as reduced kidney clearance that requires provider oversight

Domin H, Jantas D, Smialowska M

Recruitment for ME/CFS patients started just before COVID related restrictions were introduced and research was suspended: one patient and one healthy control were recruited in February 2020, others from February 2021

11 Moreover, an increasing number of nondiabetic, nonobese patients are using the GLP-1RA for weight-loss, who would not be expected to have underlying gastroparesis

The noted high efficacy of EPA/DHA supplementation, combined with its favorable acceptability and patient compliance, sets it apart from traditional pharmacological treatments, which often exhibit higher adverse event rates and lower adherence (81)